T2 Biosystems, Inc. (TTOO)
| Market Cap | 15.10M |
| Revenue (ttm) | 7.19M |
| Net Income (ttm) | -50.08M |
| Shares Out | 5.51M |
| EPS (ttm) | -19.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 411,201 |
| Open | 2.740 |
| Previous Close | 2.755 |
| Day's Range | 2.600 - 2.880 |
| 52-Week Range | 2.600 - 70.000 |
| Beta | 0.10 |
| Analysts | Hold |
| Price Target | 7.00 (+155.47%) |
| Earnings Date | May 13, 2024 |
About TTOO
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnosti... [Read more]
Financial Performance
In 2023, T2 Biosystems's revenue was $7.19 million, a decrease of -67.75% compared to the previous year's $22.31 million. Losses were -$50.08 million, -19.66% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for TTOO stock is "Hold" and the 12-month stock price forecast is $7.0.
News
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today tha...
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
LEXINGTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced res...
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced tha...
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024 Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, tod...
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes Study demonstrates T2Resistance Panel utilization enables fas...
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced tha...
T2 Biosystems (TTOO) share price stays stable post Q4 earnings
T2 Biosystems Inc. (TTOO), a prominent player in the field of medical diagnostics, recently announced its financial results for the fourth quarter of 2023, signaling a pivotal moment for the company.
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the ...
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the e...
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel
Increases number of bacteria species detected with addition of Acinetobacter baumannii Increases number of bacteria species detected with addition of Acinetobacter baumannii
T2 BioSystems stock: brace for TTOO volatility this week
T2 BioSystems (NASDAQ: TTOO) stock price has moved from one of the most popular names in Wall Street into a forgotten one. The shares have gone nowhere since October and are now sitting near their low...
T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that...
U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that ...
T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients
LEXINGTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced part...
T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that...
What's going on with T2 Biosystems (TTOO) stock?
T2 BioSystems (NASDAQ: TTOO) stock price rose by more than 23% on Tuesday amid a short-squeeze and as some investors bought the dip. The shares jumped to a high of $4.81, its highest point sice mid-No...
T2 Biosystems (TTOO) stock price volatility has died: buy the dip?
T2 Biosystems (NASDAQ: TTOO) stock price has collapsed to a record low as concerns about the company's future continued. Shares of the popular penny stock have collapsed to a split-adjusted low of $4....
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, toda...
T2 Biosystems Regains Compliance with Nasdaq Listing Requirements
LEXINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, toda...
T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference
Data demonstrates speed, accuracy, and clinical benefits of the T2Dx Instrument and T2 Biosystems' sepsis panels, including encouraging early detection data for T2Resistance Panel Data demonstrates sp...
T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement
LEXINGTON, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the s...
T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates
Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance sheet Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance shee...
T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii
LEXINGTON, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that...